Is the serum glucose/potassium ratio a reliable prognostic factor for aneurysmal SAH?
TO THE EDITOR: We studied with keen interest the article by Fujiki et al. 1 regarding the role of the serum glucose/potassium ratio in predicting the outcome of aneurysmal subarachnoid hemorrhage (SAH) (Fujiki Y, Matano F, Mizunari T, et al: Serum glucose/potassium ratio as a clinical risk factor for aneurysmal subarachnoid hemorrhage. J Neurosurg [epub ahead of print November 17, 2017. DOI: 10.3171/2017.5.JNS162799]). We commend the authors for their attempt to revisit this question because biomarkers for predicting poor prognosis following aneurysmal SAH have not yet been established. However, we would like to bring forth a few issues in this article that need further consideration. In their retrospective study design involving 565 subjects, they did not mention any inclusion or exclusion criteria. In their patient selection, there was no account of any pre-existing cause of hyperglycemia, which can be attributed to diabetes, metabolic syndrome, or insulin resistance. The drug status on admission-that is, taking oral hypoglycemic agents, insulin, or beta blockers-was not mentioned. The authors did not mention hypertensive status on admission or BMI in their summary of patient characteristics, which could have been potential confounders of a poor outcome.
There was no time cutoff from SAH to admission. The range of time from SAH to admission was 1 hour to 16 days (mean time 20.1 ± 19.07 hours). Hence, the time from SAH to admission could be an independent factor affecting prognosis, with late admissions faring worse. Moreover, the authors did not mention whether it was a single value or a mean value of serum glucose or potassium estimation at the time of admission. Also, there was no account of those patients who were normoglycemic at admission but later developed hyperglycemia. The authors report that they used sliding scale insulin for postadmission hyperglycemia control, but it would have been insightful to know the insulin dosage, which could highlight the degree of hyperglycemia and metabolic stress. The study fails to answer a pertinent question, that is, whether the glucose/potassium ratio is associated with the risk of vasospasm/delayed cerebral injury. Moreover, no correlation of the serum glucose/potassium ratio with the Glasgow Outcome Scale (GOS) score at 3 months was assessed, which misses out on patients who could have delayed recovery.
Finally, we would like to congratulate the authors on bringing to light an interesting scientific issue. Their article lays the groundwork for a larger prospective study design to evaluate these biomarkers in aneurysmal SAH to aid in treatment policy decisions.
Response
Thank you for your helpful comments regarding our article.
All patients with acute endogenous SAH (confirmed by CT or lumbar puncture) were eligible for study participation and were included if they or their health care decision surrogate provided consent. Patients with traumatic SAH and cardiopulmonary issues on arrival were excluded. Additionally, pre-existing hyperglycemia was defined by a history of diabetes, the use of oral hypoglycemic agents, the use of insulin, and an HbA1c value > 7.0. Among the 565 treated patients, 46 had these conditions of pre-existing hyperglycemia. We found that 34 patients were using oral hypoglycemic agents, 3 were using insulin, and 5 were using beta blockers. With regard to the hypertensive status and BMI of the patients, we did not find a significant correlation between a poor outcome (GOS scores 1-3) and these factors. 
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As you mentioned, for patients with severe SAH, the time from SAH to admission can be very important for deciding prognosis. However, patients with low-grade SAH, such as those who presented with mild headache, tended to undergo a late checkup at the hospital, resulting in a late admission. Thus, the data were uncorrelated with the time to admission. We apologize for not mentioning this information, but a single value of serum glucose or potassium was considered at the time of admission.
Ten patients were normoglycemic at the time of admission but later developed hyperglycemia. Among these 10 patients, 7 (70.0%) had poor outcomes (GOS scores 1-3) . However, the number of patients was not high enough to conclude a correlation with a poor outcome. Nevertheless, this situation should be considered.
With regard to the insulin dose, we believe that your point would have been insightful if we could show a correlation. However, we think that it is difficult to judge whether a patient already has diabetes or whether the shock from SAH has caused hyperglycemia because some patients with diabetes who had not been diagnosed could have been included. Sixteen patients used sliding scale insulin for post-admission hyperglycemia control, and the insulin dose was 4-52 units (mean 22.4 ± 16.0 units). Among 8 patients (50.0%) with poor outcomes (GOS scores 1-3), 5 needed insulin doses over 30 units.
We are currently working on another paper about the association of the glucose/potassium ratio with the risk of vasospasm/delayed cerebral injury, and this paper will be submitted soon. We hope that this paper will provide further clarification.
With regard to your last point, we have not provided information on that paper. However, we did analyze the correlation between the serum glucose/potassium ratio and GOS score at 1 year after discharge in 413 patients. Based on the estimation of the GOS score at 1 year after discharge, 180 patients (43.6%) were considered to have poor outcomes (GOS scores 1-3). There was a significant correlation between poor outcomes at 1 year after discharge and the serum glucose/potassium ratio. This finding indicates that we included patients who had delayed recovery.
Again, thank you for your helpful review of our article. Although one must greatly appreciate such randomized controlled trials with blinded evaluation of outcomes, there are a few methodological flaws in the trial. The authors give the impression that the experimental procedure is safe and hence equivalent to the traditional watertight cranioplasty. They come to the conclusion that rapid-closure DC without watertight duraplasty is a safe procedure and that it is not associated with a higher incidence of surgical complications. Assuming that a procedure is equivalent or non-inferior to another procedure just because there was no statistically significant difference is fundamentally wrong. Failure to reject the null hypothesis that the experimental procedure is not superior to the control procedure should not automatically prompt one to accept the null hypothesis and conclude that both procedures are equivalent in terms of safety.
Yu Fujiki, MD
In situations where one anticipates that one procedure is likely to be nearly equivalent to the other, as in the present case, a non-inferiority trial design should be used.
The authors describe a composite outcome of several complications, including CSF leak, subgaleal collection, and infective complications, as the primary outcome. The sample size should have been calculated to power the trial to find the primary outcome. However, the authors calculated sample size to find a significant difference in the duration of the surgery, which resulted in extremely low power to detect superiority in terms of complications. A retrospective calculation shows that the trial had only 5% power to detect a statistically significant difference for the primary outcome.
Consider a hypothetical example in which the control arm has only 1 complicating event compared to the same 5 complications that occurred in the experimental arm. The trial would still have shown no statistical significance! The Fisher exact test statistic value is 0.101181 (not significant, p > 0.05).
